83 FR 61659 - Prospective Grant of an Exclusive Patent License: Agonist/Antagonist Compositions and Methods of Use

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 231 (November 30, 2018)

Page Range		61659-61659
FR Document		2018-26016

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Bull Run Capital, Inc. located in Vancouver, BC, Canada.

Federal Register, Volume 83 Issue 231 (Friday, November 30, 2018)

[Federal Register Volume 83, Number 231 (Friday, November 30, 2018)]
[Notices]
[Page 61659]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-26016]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: Agonist/
Antagonist Compositions and Methods of Use

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute, an institute of the National 
Institutes of Health, Department of Health and Human Services, is 
contemplating the grant of an Exclusive Patent License to practice the 
inventions embodied in the Patents and Patent Applications listed in 
the Supplementary Information section of this notice to Bull Run 
Capital, Inc. located in Vancouver, BC, Canada.

DATES: Only written comments and/or applications for a license which 
are received by the National Cancer Institute's Technology Transfer 
Center on or before December 17, 2018 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated an Exclusive Patent License 
should be directed to: Jaime M. Greene, Senior Licensing and Patenting 
Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 
1E530 MSC 9702, Bethesda, MD 20892-9702 (for business mail), Rockville, 
MD 20850-9702; Telephone: (240) 276-5530; Facsimile: (240) 276-5504; 
Email: [email protected].

SUPPLEMENTARY INFORMATION: 

Intellectual Property

    U.S. Provisional Patent Application No. 61/340,063, filed March 12, 
2018, now abandoned, titled ``Agonist/Antagonist Compositions and 
Methods of Use'', HHS Ref. No.: E-048-2010-0-US-01;
    PCT Patent Application Serial No. PCT/US2011/028132, filed March 
11, 2011, now abandoned, HHS Reference Number E-048-2010-0-PCT-02 
titled ``Agonist/antagonist compositions and methods of use'';
    U.S. Patent 9,277,748 (Application No. 13/634,447) filed March 11, 
2011, issued March 8, 2016, titled ``Agonist/antagonist compositions 
and methods of use'', HHS Ref. No.: E-048-2010-0-US-04;
    Canada Patent Application Serial No. 2,792,878, filed March 11, 
2011, HHS Reference Number E-048-2010-0-CA-03 titled ``Agonist/
antagonist compositions and methods of use''; and
    U.S. Patent Application Serial No 15/010,830, filed January 29, 
2016, HHS Reference Number E-048-2010-0-US-05, titled ``Agonist/
antagonist compositions and methods of use''.
    The patent rights in these inventions have been assigned and/or 
exclusively licensed to the government of the United States of America.
    The prospective exclusive license territory may be worldwide and 
the field of use may be limited to: ``Use of the TRVP1 antagonists 
BCTC, AMG9810, JYL-827, Capsazepine or IodoRTX combined with a TRVP1 
agonist in a composition for the temporary incapacitation of a 
subject.''
    This technology discloses novel compositions comprising a transient 
receptor potential cation channel subfamily V member 1 (TRPV1) receptor 
agonist and an antagonist in certain ratios which allow for the onset 
of agonist action followed by alleviation by antagonist action, and 
methods of use in personal defense and law enforcement.
    Non-lethal means of temporarily incapacitating a person are needed 
for law enforcement and for personal protection. A common approach 
currently is to use pepper spray. Although current pepper sprays are 
effective, and relatively safe, for most individuals, they can be life 
threatening for people who suffer from asthma and have hypersensitive 
airways.
    In order to reduce the length of time the pepper spray can cause 
the adverse effects that could result from extended exposure, inventors 
at NCI have created a composition comprising both an incapacitating 
pepper spray TRPV1 receptor agonist compound and a slower-acting TRPV1 
receptor antagonist compound that reverses the effects of the agonist. 
The agonist/antagonist composition is intended to be used as an aerosol 
or spray, that, when administered, causes a painful stimulation and 
incapacitates a person for only a short period of time. This technology 
may fill a public health need by improving safety over currently 
available pepper sprays.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the National 
Cancer Institute receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially, and may be 
made publicly available.
    License applications submitted in response to this Notice will be 
presumed to contain business confidential information and any release 
of information in these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: November 9, 2018.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2018-26016 Filed 11-29-18; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 83, No. 231 / Friday, November 30, 2018 / Notices 61659

NIAID, NIH, 40 Convent Drive, Bethesda, MD Intellectual Property antagonist compound that reverses the
20892, (301) 496–1852, jmascola@nih.gov. effects of the agonist. The agonist/
U.S. Provisional Patent Application
Any interested person may file No. 61/340,063, filed March 12, 2018, antagonist composition is intended to be
written comments with the committee now abandoned, titled ‘‘Agonist/ used as an aerosol or spray, that, when
by forwarding the statement to the Antagonist Compositions and Methods administered, causes a painful
Contact Person listed on this notice. The of Use’’, HHS Ref. No.: E–048–2010–0– stimulation and incapacitates a person
statement should include the name, US–01; for only a short period of time. This
address, telephone number and when PCT Patent Application Serial No. technology may fill a public health need
applicable, the business or professional PCT/US2011/028132, filed March 11, by improving safety over currently
affiliation of the interested person. 2011, now abandoned, HHS Reference available pepper sprays.
Number E–048–2010–0–PCT–02 titled This notice is made in accordance
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology, ‘‘Agonist/antagonist compositions and with 35 U.S.C. 209 and 37 CFR part 404.
and Transplantation Research; 93.856, methods of use’’; The prospective exclusive license will
Microbiology and Infectious Diseases U.S. Patent 9,277,748 (Application be royalty bearing, and the prospective
Research, National Institutes of Health, HHS) No. 13/634,447) filed March 11, 2011, exclusive license may be granted unless
Dated: November 26, 2018. issued March 8, 2016, titled ‘‘Agonist/ within fifteen (15) days from the date of
antagonist compositions and methods of this published notice, the National
Natasha M. Copeland,
use’’, HHS Ref. No.: E–048–2010–0–US– Cancer Institute receives written
Program Analyst, Office of Federal Advisory
04; evidence and argument that establishes
Committee Policy.
Canada Patent Application Serial No. that the grant of the license would not
[FR Doc. 2018–26014 Filed 11–29–18; 8:45 am]
2,792,878, filed March 11, 2011, HHS be consistent with the requirements of
BILLING CODE 4140–01–P
Reference Number E–048–2010–0–CA– 35 U.S.C. 209 and 37 CFR part 404.
03 titled ‘‘Agonist/antagonist In response to this Notice, the public
compositions and methods of use’’; and may file comments or objections.
DEPARTMENT OF HEALTH AND
U.S. Patent Application Serial No 15/ Comments and objections, other than
HUMAN SERVICES
010,830, filed January 29, 2016, HHS those in the form of a license
National Institutes of Health Reference Number E–048–2010–0–US– application, will not be treated
05, titled ‘‘Agonist/antagonist confidentially, and may be made
Prospective Grant of an Exclusive compositions and methods of use’’. publicly available.
Patent License: Agonist/Antagonist The patent rights in these inventions License applications submitted in
Compositions and Methods of Use have been assigned and/or exclusively response to this Notice will be
licensed to the government of the presumed to contain business
AGENCY: National Institutes of Health, United States of America. confidential information and any release
HHS. The prospective exclusive license of information in these license
ACTION: Notice. territory may be worldwide and the applications will be made only as
field of use may be limited to: ‘‘Use of required and upon a request under the
SUMMARY: The National Cancer Institute, the TRVP1 antagonists BCTC, Freedom of Information Act, 5 U.S.C.
an institute of the National Institutes of AMG9810, JYL–827, Capsazepine or 552.
Health, Department of Health and IodoRTX combined with a TRVP1 Dated: November 9, 2018.
Human Services, is contemplating the agonist in a composition for the Richard U. Rodriguez,
grant of an Exclusive Patent License to temporary incapacitation of a subject.’’ Associate Director, Technology Transfer
practice the inventions embodied in the This technology discloses novel Center, National Cancer Institute.
Patents and Patent Applications listed compositions comprising a transient [FR Doc. 2018–26016 Filed 11–29–18; 8:45 am]
in the Supplementary Information receptor potential cation channel BILLING CODE 4140–01–P
section of this notice to Bull Run subfamily V member 1 (TRPV1) receptor
Capital, Inc. located in Vancouver, BC, agonist and an antagonist in certain
Canada. ratios which allow for the onset of DEPARTMENT OF HOMELAND
DATES: Only written comments and/or agonist action followed by alleviation by SECURITY
applications for a license which are antagonist action, and methods of use in
received by the National Cancer personal defense and law enforcement. Federal Emergency Management
Institute’s Technology Transfer Center Non-lethal means of temporarily Agency
on or before December 17, 2018 will be incapacitating a person are needed for
law enforcement and for personal [Docket ID FEMA–2018–0002]
considered.
protection. A common approach
ADDRESSES: Requests for copies of the Changes in Flood Hazard
currently is to use pepper spray.
patent application, inquiries, and Determinations
Although current pepper sprays are
comments relating to the contemplated effective, and relatively safe, for most AGENCY: Federal Emergency
an Exclusive Patent License should be individuals, they can be life threatening Management Agency, DHS.
directed to: Jaime M. Greene, Senior for people who suffer from asthma and
Licensing and Patenting Manager, NCI ACTION: Notice.
have hypersensitive airways.
Technology Transfer Center, 9609 In order to reduce the length of time SUMMARY: New or modified Base (1-
amozie on DSK3GDR082PROD with NOTICES1

Medical Center Drive, RM 1E530 MSC the pepper spray can cause the adverse percent annual chance) Flood
9702, Bethesda, MD 20892–9702 (for effects that could result from extended Elevations (BFEs), base flood depths,
business mail), Rockville, MD 20850– exposure, inventors at NCI have created Special Flood Hazard Area (SFHA)
9702; Telephone: (240) 276–5530; a composition comprising both an boundaries or zone designations, and/or
Facsimile: (240) 276–5504; Email: incapacitating pepper spray TRPV1 regulatory floodways (hereinafter
greenejaime@mail.nih.gov. receptor agonist compound and a referred to as flood hazard
SUPPLEMENTARY INFORMATION: slower-acting TRPV1 receptor determinations) as shown on the

VerDate Sep<11>2014 17:00 Nov 29, 2018 Jkt 247001 PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 E:\FR\FM\30NON1.SGM 30NON1

Document Created: 2018-11-30 04:35:57
Document Modified: 2018-11-30 04:35:57

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice.
Dates		Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before December 17, 2018 will be considered.
FR Citation		83 FR 61659

83 FR 61659 - Prospective Grant of an Exclusive Patent License: Agonist/Antagonist Compositions and Methods of Use

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 83, Issue 231 (November 30, 2018)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health